4 results about "Virus infected cell" patented technology

Disclosed herein is a small molecule targeted drug conjugate for anti-influenza chemotherapy and immunotherapy. The disclosed drug conjugate may form an adaptor to recruit additional CAR T cells or other immune cells for precise elimination of influenza virus-infected cells in a subject. Concurrently administered antibodies or pre-existing immunity in influenza-virus infected subject works well with the targeted conjugate to eliminate virus infected cells, saving valuable time for rescuing late stage patients.

The application provides a kind of 2,6-piperidinedione derivatives and preparation method and application thereof.The compound has the structure shown in the following formula I, formula II or formula III:2,6-piperidinedione derivatives described in the application can induce the degradation of GSPT1 protein, and have cytotoxic effect on cancer cells.Therefore, the compound and composition provided by the application can be used for preparing drugs for treating or preventing tumor formation, inflammation, viral infection, cell proliferative disorder, autoimmune disease, sepsis and other related diseases.

The application provides a polypeptide molecule for specifically recognizing HIV gp120 protein and an application thereof, and belongs to the technical field of biological medicine. The application provides a lead polypeptide derivative for specifically targeting and combining HIV gp120, wherein the lead polypeptide comprises an amino acid sequence shown in SEQ ID No. 1. The application also provides a lead polypeptide derivative prepared based on the lead polypeptide, and a polypeptide nanoparticle constructed by the lead polypeptide derivative, and both of them have gp120 protein combining capacity. The derivative and the nanoparticle have good virus neutralization inhibition effect. The series of polypeptide molecules can specifically combine with free HIV virus, HIV infected cells and free gp120, so as to block HIV infected cells, delay the AIDS disease process, realize AIDS treatment drug targeted delivery, detection and diagnosis.

This invention belongs to the field of virus-infected cell line technology, and particularly relates to a striped field mouse lung cell line and its applications. The striped field mouse lung cell line has the accession number CCTCC NO: C2025268. The AaL-09W cell line (including primary and passaged cells) provided by this invention has multiple advantages, including high sensitivity to Hantavirus, high replication efficiency, high isolation success rate, closer resemblance to the host's natural environment, passage stability, and easy scaling-up. It provides a reliable cellular tool and an efficient, reliable, and scalable experimental platform for the isolation, identification, in vitro culture, titer determination, infection mechanism and pathogenesis research, new drug screening, and vaccine development of Hantavirus, meeting the needs of efficient culture and multi-scenario applications of HTNV and related Hantaviruses.